CD274 and hepatocellular carcinoma: Due to its potent therapeutic effects against human malignancies, ICT has entered clinical trials for the treatment of PD-L1-positive advanced HCC (Phase III, ClinicalTrials, NCT03236649), HCC (Phase III, ClinicalTrials, NCT03236636), advanced solid tumors (Phase Ib, completed, ClinicalTrials, NCT02496949), and advanced breast cancer (Phase I, ClinicalTrials, NCT01278810).